Issues in the Management of Hemophilia: A Best Practice Series

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Trials in IBD.

Psoriatic Arthritis.

Why Gene Therapy for Hemophilia?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Thrombosis, Cancer, and NOACs

Progression After Cancer Immunotherapy in Advanced NSCLC

Ask the Onychomycosis Expert, Part 2

Ask the Onychomycosis Expert, Part 1

New Standards of Care in ALK-Translocated Advanced NSCLC

Improving Acne Outcomes

Hemophilia Updates: Incorporating New Concepts Into Practice

Extended Half-life Factor Products in the Management of Hemophilia

Individualizing Prophylaxis in Hemophilia

Hot Topics in Hemophilia Nursing

Case Challenges in Chronic Migraine

Advances in Dry Eye.

Mid-Year Hemophilia Update

Before and After: Patient Cases in Onychomycosis

Treat to Target in Gout.

PARP Inhibitors and Cancer: What Do You Need to Know?

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Tailoring Hemophilia Prophylaxis Therapy

The Nurse View.

Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice

Asthma and Atopic Comorbidities

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Evaluating Next-Generation BTK Inhibitors

Issues in the Management of Hemophilia: A Best Practice Series

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Ask the Experts.

Immunotherapy for cSCC

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

Parkinson Disease Psychosis

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Advances in Immunotherapy for Peanut Allergy

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Extended Half-life Factor Products in the Management of Hemophilia

The Burden of Psoriasis:

Current Challenges in Managing Hemophilia

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Optimizing Joint Health in Hemophilia

Pregnancy in MS.

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

First-Line FCR: Effect of del(17p) on PFS and OS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

VKA Reversal and LVADs.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Issues in the Management of Hemophilia: A Best Practice Series

Optimizing Prophylaxis in Children With Hemophilia

This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the US.

Introduction

Case 1 Newly Diagnosed Hemophilia

Classification of Hemophilia

When to Start Primary Prophylaxis

Origin of Prophylaxis for Hemophilia A

How to Start Primary Prophylaxis

Challenges With Venous Access

Trends in CVAD Use

Options for Factor Replacement

New Recombinant Factor Concentrate

EHL Factor Products

Adoption of EHL Factor Into Practice

Approach in Other Countries

Inhibitors

Monitoring for Inhibitor Formation

The SIPPET Study

SIPPET Implications for Previously Untreated Patients

SIPPET Implications for Existing Patients

Case 2 Boy With High-Titer Inhibitor

ITI Study

When to Start ITI

Treating Bleeds in Patients With High Titer

Case 3 Bleeding in a Teenager

Prophylaxis Adherence in Teenagers

Conclusions

Abbreviations

Abbreviations